

4 April 2016 EMA/76589/2016 Press office

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures

Adopted at the CHMP meeting of 29 March – 1 April 2016

Table 1. Opinions for annual re-assessment applications

| Name of medicinal product (INN) MAH | Outcome | Comments |
|---|------------------|---|
| Ceplene, (histamine dihydrochloride), Meda AB | Positive Opinion | Marketing Authorisation remains under exceptional circumstances |
| Xagrid, (anagrelide), Shire Pharmaceutical Contracts Ltd. | Positive Opinion | Marketing Authorisation remains under exceptional circumstances |

Table 2. Opinion for renewals of conditional Marketing Authorisation

| Name of medicinal product (INN) MAH | Outcome | Comments |
|---|------------------|---|
| Erivedge , (vismodegib), Roche Registration Limited | Positive Opinion | Recommending renewal of conditional Marketing Authorisation |
| Fampyra, (fampridine), Biogen Idec Ltd., | Positive Opinion | Recommending renewal of conditional Marketing Authorisation |

Table 3. Opinion for 5-Year Renewal applications

| Name of medicinal product (INN) MAH | Outcome | Comments |
|---|------------------|--------------------|
| Buccolam, (midazolam), Shire Services BVBA | Positive Opinion | Unlimited validity |



| Name of medicinal product (INN) MAH | Outcome | Comments | |
|---|------------------|---------------------------------|--|
| Vibativ, (telavancin), Clinigen Healthcare Ltd, | Positive Opinion | Recommending additional renewal | |
| Cayston, (aztreonam), Gilead Sciences International Ltd | Positive Opinion | Unlimited validity | |
| Cinryze, (C1-esterase inhibitor, human), Shire Services BVBA | Positive Opinion | Unlimited validity | |
| Levodopa/Carbidopa/Enta capone Orion, (levodopa / carbidopa / entacapone), Orion Corporation | Positive Opinion | Unlimited validity | |
| Zytiga, (abiraterone), Janssen-Cilag International N.V. | Positive Opinion | Unlimited validity | |
| Dexdor, (dexmedetomidine), Orion Corporation | Positive Opinion | Unlimited validity | |

 Table 4. Accelerated assessment procedures

| INN | Intended indication(s) | Accelerated Assessment Request | |
|-------------------------------|---|--------------------------------|----------|
| | | Accepted | Rejected |
| Monoclonal Antibody Sgn-30 | treatment of metastatic colorectal cancer | Х | |